In this double-blind phase III clinical trial, patients with newly diagnosed ovarian cancer and a BRCA mutation (germline or somatic) who responded to platinum-based chemotherapy were randomized to receive Olaparib or placebo for up to 2 years. After a 7-year follow-up, prespecified analysis of overall survival was reported.
This is the longest follow-up of a PARP inhibitor in the first-line setting that revealed clinically meaningful improvements in overall survival for patients treated with Olaparib.
At 7 years, 67.0% of Olaparib patients versus 46.5% of placebo patients were alive, and 45.3% versus 20.6%, respectively, were alive and had not received a first subsequent treatment (Kaplan-Meier estimates).
The results support the use of maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation to achieve long-term remission.
